BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

11:05 AM
May 25, 2018
 |  BioCentury  |  Finance

HKEX’s on-demand experts

How HKEX plans to leverage its biotech advisory panel

The Hong Kong stock exchange is well aware its investor base is new to the high-risk, high-reward nature of its newly hatched biotech chapter and has no qualms about admitting its own lack of expertise. Its solution is a star-studded advisory panel to identify problems that could sink the sector before it gets off the ground.

On May 4, Hong Kong Exchanges and Clearing Ltd. (HKEX) announced the formation of a biotech advisory panel composed of 13 KOLs from China’s academic, corporate, investment and regulatory communities.

The announcement followed the formal implementation of the exchange’s biotech chapter on April 30, which cleared the way for pre-revenue and pre-profit biotech companies to publicly list and raise capital on HKEX for the first time.

At launch, the exchange issued guidances and built in gating criteria, including suitability tests, listing requirements and shareholder protections to provide quality control over its listings.

But interpreting these rules is still beyond the scope of the exchange’s capabilities, meaning low-quality issuers could still slip through. Poor decisions in the chapter’s infancy could sour interest in the space and have lasting effects.

The advisory panel is the next step to mitigate those risks and ensure the exchange is not tripped up by its own blind spots. The idea is to provide a source of ad hoc consultants for the listing committee, particularly for guidance on company-specific disclosures.

The exchange’s initial advisory group includes leading entrepreneurs and investors with a proven track record of global success in the biotech sector (see “Meet the Panelists”).

“Many of the people who we’ve got in there, they’re not people who are generally just from the Hong Kong or China market,” said James Fok, head of group strategy at HKEX. “They have international or global expertise.”

Table: Meet the panelists

Hong Kong Exchanges and Clearing Ltd.’s (HKEX) biotech advisory panel has world-class experience spanning the academic, corporate, investment and regulatory spheres. Seven of the panelists hold executive or board positions within a biotech or medical device company, and five have roles in academia and/or the investment community, with one holding both types of positions. Stakeholders told BioCentury the advisory panel has the right consistency, though it would benefit from the addition of leaders in the fields of patent law, M&A and licensing, epidemiology and market research. Source: HKEX press releases, HKEX website, company and institution reports

PanelistCurrent role(s)Notable prior role(s)
Samantha Du  Co-founder of Zai Lab Ltd. (NASDAQ:ZLAB)Managing director of healthcare investments at Sequoia Capital China; co-founder of Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM)
Victoria ElegantVP and regional head, medical at Amgen Inc. (NASDAQ:AMGN)VP, regulatory and medical affairs, APAC at Baxter International Inc. (NYSE:BAX); VP, medical affairs, Asia at Shire plc (LSE:SHP; NASDAQ:SHPG) (formerly...

Read the full 2341 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >